Deciphering the synergistic mechanism of a novel flavonoid-antioxidant combination for asthma by combining systems pharmacology and experimental validation

Z Ziyi Chen (Key Laboratory of Biomedical Polymers Ministry of Education, College of Chemistry and Molecular Sciences) X Xinling Ren X Xiaoyu Liu (Optogenetics & Synthetic Biology Interdisciplinary Research Center, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China) L Lifeng Tian Y Yun Huang A Aiping Lyu W Wei Zhou

Abstract

Asthma is a multifaceted disorder characterized by an intricate interplay of various pathophysiological processes, including airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. This complexity encompasses a multitude of genetic, molecular, and environmental factors, making it challenging to identify effective strategies for prevention and treatment. Research into the pathogenesis and treatment of asthma continues in the pursuit of more comprehensive and targeted therapeutic approaches. The asthma pathology has been shown to be influenced by the flavonoid 7,4′- Dihydroxyflavone (74DHF), which is extracted from the herb Rhizoma Glycyrrhizae (Gancao), while taking the antioxidant ascorbic acid (VC) daily through food or supplements contributes to the treatment of asthma related to immunomodulatory regulation. However, the potential molecular or systemic mechanism of the combination of 74DHF and VC in treating asthma has yet to be fully understood, despite the demonstrated individual benefits of each compound. The present study employed a systems pharmacology strategy, combining target identification, network analysis, data integration, Gene Ontology (GO) enrichment analysis, pathway analysis, and in vitro experimental validation to uncover the synergistic pharmacological mechanisms of 74DHF-VC combination for asthma therapy. The results identified 153 and 308 targets for 74DHF and VC, 37 overlapping targets and 20 hub targets among 74DHF, VC, and asthma. Based on the GO and pathway analysis, 10 optimal common GO processes and 10 key canonical pathways were enriched, which were closely related to the combination therapy of 74DHF and VC against asthma. In addition, the in vitro experiments validated that 74DHF and VC had synergistic effects on anti-inflammation and fibrosis. The combined treatment reversed the LPS induced inflammation in macrophages and TGF-β induced cell migration and fibrosis in lung epithelial cells. The current study not only successfully explains the synergistic mechanisms underlying the efficiency of 74DHF and VC against asthma but also proposes a viable and promising strategy to fasten the process of combination treatment.

Article Details

Journal PLoS ONE
Volume / Issue Vol. 21, Issue 3
Published March 30, 2026
Pages e0346165
ISSN 1932-6203
Publisher Public Library of Science

Journal Info

PLoS ONE

Public Library of Science

ISSN: 1932-6203 Open Access Health Sciences

Authors (7)

Z

Ziyi Chen

Key Laboratory of Biomedical Polymers Ministry of Education, College of Chemistry and Molecular Sciences

X

Xinling Ren

X

Xiaoyu Liu

Optogenetics & Synthetic Biology Interdisciplinary Research Center, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China

L

Lifeng Tian

Y

Yun Huang

A

Aiping Lyu

W

Wei Zhou